Vertex reports data from early-stage cystic fibrosis studies | PeptiDream collaborates with Kleo for immuno-oncology drug research | Cogentix, Promepla enter exclusive license deal
July 20, 2017
Aon Life Sciences Advisor
SIGN UP ⋅   FORWARD
Top Stories
Vertex reports data from early-stage cystic fibrosis studies
Trials of investigative treatments for cystic fibrosis from Vertex Pharmaceuticals have found improved outcomes for patients who do not respond to current treatments through the addition of three different compounds to regimens of ivacaftor and tezacaftor. Vertex may choose one triple-combo this year to advance to late-stage trials next year.
Xconomy (7/18),  The Wall Street Journal (tiered subscription model) (7/19) 
LinkedIn Twitter Facebook Google+ Email
PeptiDream collaborates with Kleo for immuno-oncology drug research
Tokyo-based PeptiDream agreed to work with Kleo Pharmaceuticals on the development of immuno-oncology drugs for multiple indications using PeptiDream's Peptide Discovery Platform System technology to identify peptides against targets selected by Kleo. Under the deal, Kleo will get an upfront payment and retain rights to develop and market products resulting from the agreement, while PeptiDream will receive a tiered portion of the proceeds.
Genetic Engineering & Biotechnology News (7/18) 
LinkedIn Twitter Facebook Google+ Email
Other News
Liability and Safety
Mallinckrodt settles opioid drug allegations for $35M
Mallinckrodt settles opioid drug allegations for $35M
(John Moore/AFP/Getty Images)
Mallinckrodt, which is said by US authorities to be one of the largest makers of generic oxycodone, agreed to pay $35 million to resolve allegations that it violated provisions of the Controlled Substances Act when it failed to discover suspicious orders of controlled substances and notify the US Drug Enforcement Administration. The DEA said Mallinckrodt's alleged failure to follow record-keeping requirements at its Hobart, N.Y., plant caused discrepancies between the number of tablets manufactured and the number reported, although the company denies the allegations and says the "settlement contains no admission of liability for civil penalties for relevant conduct."
The Daily Star (Oneonta, N.Y.) (tiered subscription model) (7/19) 
LinkedIn Twitter Facebook Google+ Email
 
Business and Market Trends
Drugmakers may be reconsidering price models
Drugmakers are starting to take responsibility and work with pharmacy benefit managers to make their products more affordable, says Express Scripts Chief Medical Officer Steve Miller. The prices on three new drugs were lower than expected, and Miller says there is "recognition by certain pharmaceutical manufacturers that they are in control of their price and can do something."
FiercePharma (7/17) 
LinkedIn Twitter Facebook Google+ Email
Other News
Government and Regulatory
Health Care and Policy
HCV drug from Gilead wins FDA approval
Gilead Sciences' single-tablet Vosevi, or sofosbuvir 400 mg/velpatasvir 100 mg/voxilaprevir 100 mg, has been approved by the FDA as a treatment for adult patients with chronic hepatitis C virus with genotypes 1 through 6 who had prior treatment with a regimen containing an NS5A inhibitor. The drug is also approved for HCV patients with genotype 1a or 3 who were previously treated with a regimen containing sofosbuvir without an NS5A inhibitor.
Seeking Alpha (free registration) (7/18) 
LinkedIn Twitter Facebook Google+ Email
Other News
Company and Financial News
Private placement raises $18.2M for Uni-Bio
A private placement brought in $18.2 million for Uni-Bio Science Group, which recently launched the insulin secretagogue Bokangtai, or mitiglinide, a generic version of Kissei Pharmaceutical's Glufast.
BioCentury (7/18) 
LinkedIn Twitter Facebook Google+ Email
Other News
News from Aon
Aon announces Q2 2017 earnings release and conference call
Aon plans to announce second-quarter and full-year 2017 results on Friday, Aug. 4, in a news release to be issued before the market opens. Greg Case, president and CEO, will host a conference call at 7:30 a.m. Central time on Aug 4. Read more.
LinkedIn Twitter Facebook Google+ Email
How to harness the talent of the on-demand workforce
There's no better time to get something than at exactly the moment you need it. The rapid growth of the "on-demand" economy, where goods and services are ordered online and delivered promptly, has meant a new way of doing business -- and working. How are businesses harnessing this on-demand talent? Learn more.
LinkedIn Twitter Facebook Google+ Email
  
  
There is no end. There is no beginning. There is only the infinite passion of life.
Federico Fellini,
film director
LinkedIn Twitter Facebook Google+ Email
  
  
Learn more about Aon Life Sciences:
Aon Home Page | Aon Life Sciences
Thought Leadership | Media Room
About Aon Life Sciences Practice
Aon provides Life Sciences companies with end-to-end risk solutions, supporting organizations from the initial discovery phase to final product launch. The practice provides solutions across the Life Sciences for pharmaceutical manufacturers; generic and OTC pharmaceutical companies; biotechnology and biopharmaceutical companies; genomic and proteomic companies; drug delivery system; diagnostic substance companies; and medical device and equipment manufacturers.

Contact Aon
Aon Risk Solutions – Life Sciences
James Walters, Global Practice Leader
+1.215.255.1795
james.walters@aon.com
www.aon.com

 Linkedin Twitter
About Aon
Aon plc (NYSE:AON) is a leading global professional services firm providing a broad range of risk, retirement and health solutions. Our 50,000 colleagues in 120 countries empower results for clients by using proprietary data and analytics to deliver insights that reduce volatility and improve performance.
Powered By SmartBrief
Subscriber Tools:
Contact Us:
Editor  -  Tara Rosenzweig
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2017 SmartBrief, Inc.®
Privacy policy |  Legal Information